FDA OKs Shire ADHD drug Vyvanse

Share this article:
The FDA Friday granted approval to Shire’s Vyvanse (lisdexamfetamine) as a treatment for attention deficit hyperactivity disorder (ADHD). Shire hopes the drug, which is harder to abuse than older stimulants, will revitalize the company’s ADHD franchise, once Adderall XR begins facing generic competition in 2009. Adderall XR brought in approximately $975 million in sales for Shire in 2005, followed by McNeil Consumer and Specialty Pharmaceuticals’ Concerta with sales of $838 million and Eli Lilly’s Strattera, with sales of $662 million. Shire developed Vyvanse in conjunction with New River Pharmaceuticals of Radford, VA. Shire acquired New River in a deal worth $2.6 billion last week.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.